Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321058 | 1.00 | GPR119 (0.50) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL3321062 | 1.00 | GPR119 (0.50) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL9948274 | 0.89 | GPR119 (0.50) | GPR119USP30ADORA2AADORA2BADORA3 | |
| SCHEMBL1328780 | 0.86 | GPR119 (0.60) | GPR119USP30ADORA2AADORA2BGRM5 | |
| SCHEMBL3325433 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 | |
| SCHEMBL12631529 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 | |
| SCHEMBL3325441 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 | |
| SCHEMBL970903 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 | |
| SCHEMBL3325435 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 | |
| SCHEMBL970901 | 0.83 | USP30 (0.53) | GPR119USP30HPGDSPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | GPR119 178/4885USP30 1430/4885ADORA2A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.